Synonyms: AMG203 [5] | MT203
Compound class:
Antibody
Comment: Namilumab (AMG203, MT203) is an IgG1κ anti-macrophage colony-stimulating factor (GM-CSF; CSF2) monoclonal antibody [2]. It is being developed by Micromet and Nycomed for the treatment of autoimmune and chronic inflammatory diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB entry. |
Bioactivity Comments |
Namilumab does not bind to either of the other colony-stimulating factors (G-CSF or M-CSF) [2]. It potently neutralises recombinant human GM-CSF produced in E. coli and yeast expression systems, and endogenous GM-CSF from human bronchial epithelial cells. It also binds and neutralises macaque GM-CSF. |
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|